End-of-treatment anti-HBs levels and HBeAg status identify durability of HBsAg loss after PEG-IFN discontinuation

BACKGROUND: Hepatitis B surface antigen (HBsAg) loss, namely, the functional cure, can be achieved through the pegylated interferon (PEG-IFN)-based therapy. However, it is an unignorable fact that a small proportion of patients who achieved functional cure develop HBsAg reversion (HRV) and the relat...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Yifei, Han, Jiajia, Zhang, Yongmei, Jin, Chengmeng, Zhang, Yao, He, Jingjing, Chen, Shiqi, Guo, Yue, Lin, Yanxue, Li, Fahong, Yang, Feifei, Shen, Zhongliang, Mao, Richeng, Zhu, Haoxiang, Zhang, Jiming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Cellular and Infection Microbiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9998526/
https://www.ncbi.nlm.nih.gov/pubmed/36909726
http://dx.doi.org/10.3389/fcimb.2023.1120300

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9998526/
https://www.ncbi.nlm.nih.gov/pubmed/36909726
http://dx.doi.org/10.3389/fcimb.2023.1120300

Ejemplares similares